See more section
James’ practice focuses on capital markets and securities matters, including public and private offerings and SEC compliance, as well as support for life sciences transactions.
His experience includes initial public offerings (IPOs), private investments in public equity (PIPEs), registered directs (RDs), confidentially marketed public offerings (CMPOs), rights offerings, and special purpose acquisition companies (SPACs).
James also represents clients such as funds and investment banks on issues involving formation, corporate governance, joint ventures, and tender offers.
A former associate in the life sciences group at an Am Law 50 firm, James has worked with pharmaceutical, consumer healthcare, biotech, and medical device companies on a variety of transactional, operational, and general corporate matters, including corporate governance, mergers and acquisitions, licensing of products and intellectual property, collaboration and development agreements, and various other commercial agreements.
James has over 12 years of experience at large pharmaceutical corporations, including Merck, where he served in the Corporate Transactions department of the General Counsel’s office; and Novartis, where he worked in preclinical research and development.